PL352365A1 - Neuroprotective and retinoprotective ophthalmologic medicines - Google Patents

Neuroprotective and retinoprotective ophthalmologic medicines

Info

Publication number
PL352365A1
PL352365A1 PL00352365A PL35236500A PL352365A1 PL 352365 A1 PL352365 A1 PL 352365A1 PL 00352365 A PL00352365 A PL 00352365A PL 35236500 A PL35236500 A PL 35236500A PL 352365 A1 PL352365 A1 PL 352365A1
Authority
PL
Poland
Prior art keywords
neuroprotective
ramiprilat
medicine
visual
acuity
Prior art date
Application number
PL00352365A
Other languages
English (en)
Inventor
Raouf Rekik
Original Assignee
Rekik Elyes Ben Mohamed Raouf
Raouf Rekik
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9915359A external-priority patent/FR2794975A1/fr
Application filed by Rekik Elyes Ben Mohamed Raouf, Raouf Rekik filed Critical Rekik Elyes Ben Mohamed Raouf
Publication of PL352365A1 publication Critical patent/PL352365A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
PL00352365A 1999-06-16 2000-06-16 Neuroprotective and retinoprotective ophthalmologic medicines PL352365A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TN99122 1999-06-16
FR9915359A FR2794975A1 (fr) 1999-06-16 1999-12-06 Medicaments opthalmologiques neuro et retino-protecteurs

Publications (1)

Publication Number Publication Date
PL352365A1 true PL352365A1 (en) 2003-08-25

Family

ID=26235177

Family Applications (1)

Application Number Title Priority Date Filing Date
PL00352365A PL352365A1 (en) 1999-06-16 2000-06-16 Neuroprotective and retinoprotective ophthalmologic medicines

Country Status (20)

Country Link
US (1) US7049340B1 (de)
EP (1) EP1185255B1 (de)
JP (1) JP2003501461A (de)
AT (1) ATE424819T1 (de)
AU (1) AU6449000A (de)
BR (1) BR0011714A (de)
CA (1) CA2376909A1 (de)
CZ (1) CZ20014516A3 (de)
DE (1) DE60041765D1 (de)
DK (1) DK1185255T3 (de)
ES (1) ES2324200T3 (de)
HU (1) HUP0201478A3 (de)
MA (1) MA26798A1 (de)
MX (1) MXPA01012907A (de)
NO (1) NO20016088L (de)
PL (1) PL352365A1 (de)
SI (1) SI1185255T1 (de)
SK (1) SK18772001A3 (de)
TR (1) TR200103665T2 (de)
WO (1) WO2000076499A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2826276A1 (fr) * 2001-06-20 2002-12-27 Raouf Rekik Administration des inhibiteurs de l'enzyme de conversion de l'angiotensine dans les degradations visuelles des sujets ages dues a la presbytie
EP2021000A2 (de) * 2006-05-09 2009-02-11 Braincells, Inc. Neurogenese mittels angiotensin-modulation
US7858611B2 (en) 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
TNSN08110A1 (en) * 2008-03-11 2009-07-14 Rekik Raouf Dr Drug delivery to the anterior and posterior segment of the eye from drops
TN2010000566A1 (en) * 2010-12-03 2012-05-24 Rekik Raouf Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs
RU2471454C2 (ru) * 2010-12-14 2013-01-10 Валерий Викторович Педдер Способ лечения дистрофических заболеваний сетчатки глаза
CA2877590A1 (en) * 2012-06-29 2014-01-03 Raouf Rekik Angiotensin converting enzyme inhibitors for treating optic neuropathy or congenital optic atrophy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3381850D1 (de) * 1982-12-27 1990-10-04 Schering Corp Pharmazeutische zusammensetzung.
DE3410732A1 (de) * 1984-03-23 1985-09-26 Hoechst Ag, 6230 Frankfurt Methode zur behandlung des glaukoms
US4656188A (en) * 1985-10-09 1987-04-07 Merck & Co., Inc. Ace inhibitors in macular degeneration
JPH05306296A (ja) * 1992-04-24 1993-11-19 Marino Forum 21 魚類由来ペプチドとその製法
WO1999036062A1 (en) * 1998-01-16 1999-07-22 Alcon Laboratories, Inc. Topical administration of angiotensin-converting enzyme inhibitors

Also Published As

Publication number Publication date
CA2376909A1 (fr) 2000-12-21
US7049340B1 (en) 2006-05-23
SI1185255T1 (sl) 2009-08-31
AU6449000A (en) 2001-01-02
HUP0201478A2 (hu) 2002-11-28
ATE424819T1 (de) 2009-03-15
SK18772001A3 (sk) 2002-04-04
MA26798A1 (fr) 2004-12-20
DK1185255T3 (da) 2009-07-06
DE60041765D1 (de) 2009-04-23
ES2324200T3 (es) 2009-08-03
EP1185255A2 (de) 2002-03-13
MXPA01012907A (es) 2003-06-24
TR200103665T2 (tr) 2002-10-21
CZ20014516A3 (cs) 2002-05-15
EP1185255B1 (de) 2009-03-11
NO20016088D0 (no) 2001-12-13
HUP0201478A3 (en) 2004-05-28
WO2000076499A2 (fr) 2000-12-21
JP2003501461A (ja) 2003-01-14
NO20016088L (no) 2002-02-12
BR0011714A (pt) 2002-03-05
WO2000076499A3 (fr) 2001-05-17

Similar Documents

Publication Publication Date Title
AU766216C (en) Method for the treatment of cerebral ischaemia and use of erythropoietin or erythropoietin derivatives for the treatment of cerebral ischaemia
CA2391539A1 (en) Use of poly(diallylamine) polymers
WO2004028570A3 (en) A method for treating severe tinnitus
NO20002005L (no) FremgangsmÕte for behandling av hyperkoagulable tilstander eller protein C mangel
TW200607511A (en) Use of optically pure (S,S)-reboxetine in the manufacture of a medicament for the treatment or prevention of peripheral neuropathy
EP1118325A3 (de) Arzneistoffabgabesysteme enthaltend Mikrotubulstabilisatoren und deren Verwendung zur Herstellung eines Medikaments für die Behandlung Artherosklerose oder Restenos
BG103372A (en) PHARMACEUTICAL COMPOSITION INCLUDING AN ANTI-Xa- ACTIVITY BELONGING COMPOUND AND AN ANTAGONIST COMPOUND OF THROMBOCYTE AGGREGATION
US10188676B2 (en) Anti-inflammatory solution
WO2001019334A3 (en) Pharmaceutical solutions of levosimendan
AU696954B2 (en) Antithrombotic and non-hemorrhagic heparin-based compositions, process for their preparation and therapeutic applications
AU1146295A (en) Products containing G-CSF and TNF binding protein
EP1074258A3 (de) Verfahren und Zusammensetzungen zur Behandlung von Augenerkrankungen und -Zuständen
SI1185255T1 (sl) Retinoprotektivna oftalmološka zdravila, ki obsegajo ramipril ali ramiprilat
Bucci Jr et al. Branch retinal artery occlusion secondary to percutaneous transluminal coronary angioplasty.
RU2001118854A (ru) Оптически активное производное пиридил-4н-1,2,4-оксадиазина и его применение при лечении сосудистых заболеваний
AU3401093A (en) Therapeutic agent for threatened abortion
Quah et al. A Review of 5 Years' Experience in the Use of Botulinum Toxin A in the Treatment of Sixth Cranial Nerve Palsy at Singapore National Eye Centre
EP0410749A3 (en) Anthocyanidins for the treatment of ophthalmic diseases
WO2003006002A8 (en) Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
AU2001223953A1 (en) Use of l-carnitine as stabilizing agent of proteins
RU2148972C1 (ru) Способ лечения гемофтальма
DE69431430D1 (de) Faktor XIII zur Behandlung von Hautwunden
WO2001028578A3 (en) A PHARMACEUTICAL COMPOSITION CONTAINING pGLU-GLU-PRO-NH2 AND METHOD FOR TREATING DISEASES AND INJURIES TO THE BRAIN, SPINAL CORD AND RETINA USING SAME
WO1999006438A3 (en) Compounds with anti-ks and anti-hiv activity
CY1110476T1 (el) Οφθαλμολογικα φαρμακα προστατευτικα του αμφιβληστροειδους τα οποια περιεχουν ραμιπριλη ή ραμιπριλατη

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)